David W Hammers Selected Research

prednylidene (Pred)

1/2020

Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David W Hammers Research Topics

Disease

4	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 05/2024 - 01/2016
4	Ischemia 04/2015 - 10/2008
3	Muscular Dystrophies (Muscular Dystrophy) 10/2019 - 01/2016
2	Neoplasms (Cancer) 02/2023 - 01/2023
2	Pancreatic Neoplasms (Pancreatic Cancer) 02/2023 - 01/2023
2	Fibrosis (Cirrhosis) 10/2022 - 01/2020
1	Disease Progression 10/2022
1	Muscular Atrophy (Muscle Atrophy) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Hypertrophy 10/2019
1	Muscle Weakness 10/2019
1	Fatigue 01/2019
1	Sarcoglycanopathies 01/2019
1	Wasting Syndrome (Wasting Disease) 01/2017
1	Cardiomyopathies (Cardiomyopathy) 01/2016
1	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/2016
1	Reperfusion Injury 11/2015

Drug/Important Bio-Agent (IBA)

4	Insulin-Like Growth Factor I (IGF-1)IBA 10/2019 - 04/2011
3	DystrophinIBA 05/2024 - 01/2016
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 02/2023 - 01/2023
1	NADPH Oxidases (NAD(P)H oxidase)IBA 10/2022
1	prednylidene (Pred)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Insulin-Like PeptidesIBA 10/2019
1	DysferlinIBA 10/2019
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	edasalonexentIBA 12/2016
1	TRPC6 Cation ChannelIBA 01/2016
1	Tadalafil (Cialis)FDA Link 01/2016
1	Threonine (L-Threonine)FDA Link 01/2016
1	CalpainIBA 01/2016
1	Peptide Hydrolases (Proteases)FDA Link 01/2016
1	m-calpainIBA 01/2016
1	activin receptor type II-BIBA 01/2016
1	UtrophinIBA 01/2016
1	Phosphodiesterase 5 InhibitorsIBA 01/2016
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 01/2016
1	Chemokine CXCL12IBA 11/2015

Therapy/Procedure

4	Tourniquets 11/2015 - 10/2008
3	Therapeutics 10/2022 - 01/2016
1	Treatment Delay 01/2016